EP Patent

EP4063391A1 — Anti-kit antibodies and uses thereof

Assigned to Celldex Therapeutics Inc · Expires 2022-09-28 · 4y expired

What this patent protects

The invention provides an antibody, or antigen-binding fragment thereof, or a conjugate comprising the antibody or antigen-binding fragment thereof linked to an agent, for use in a method of treating or managing a KIT-associated disorder, wherein said antibody or antigen-binding …

USPTO Abstract

The invention provides an antibody, or antigen-binding fragment thereof, or a conjugate comprising the antibody or antigen-binding fragment thereof linked to an agent, for use in a method of treating or managing a KIT-associated disorder, wherein said antibody or antigen-binding fragment thereof immunospecifically binds to human KIT and inhibits tyrosine phosphorylation of KIT with an IC50 of about 600 pM or less as determined by ELISA, and wherein the antibody or antigen-binding fragment thereof induces KIT receptor internalization.

Drugs covered by this patent

Patent Metadata

Patent number
EP4063391A1
Jurisdiction
EP
Classification
—
Expires
2022-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Celldex Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.